Aquestive Therapeutics (NASDAQ:AQST) Insider Peter Boyd Sells 10,000 Shares

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Peter Boyd sold 10,000 shares of the firm’s stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $6.30, for a total value of $63,000.00. Following the transaction, the insider owned 278,323 shares of the company’s stock, valued at $1,753,434.90. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Aquestive Therapeutics Price Performance

AQST stock opened at $5.65 on Tuesday. The firm has a market capitalization of $563.42 million, a P/E ratio of -8.07 and a beta of 1.82. The business’s 50-day moving average is $4.40 and its two-hundred day moving average is $3.52. Aquestive Therapeutics, Inc. has a 1 year low of $2.12 and a 1 year high of $6.43.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $10.00 million during the quarter, compared to analyst estimates of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Analysts Set New Price Targets

AQST has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Zacks Research raised Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 13th. Oppenheimer increased their price target on Aquestive Therapeutics from $7.00 to $8.00 and gave the company an “outperform” rating in a research report on Monday, September 8th. Finally, Lifesci Capital raised Aquestive Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $10.29.

Institutional Investors Weigh In On Aquestive Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets raised its position in shares of Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after acquiring an additional 4,134 shares in the last quarter. Summit Wealth & Retirement Planning Inc. acquired a new position in Aquestive Therapeutics during the first quarter worth approximately $29,000. USAdvisors Wealth Management LLC acquired a new position in Aquestive Therapeutics during the second quarter worth approximately $33,000. Modern Wealth Management LLC acquired a new position in Aquestive Therapeutics during the second quarter worth approximately $33,000. Finally, Victory Capital Management Inc. acquired a new position in Aquestive Therapeutics during the first quarter worth approximately $31,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.